"id","description","instanceType","rationale","name","label","uuid:ID"
"StudyDesign_1","The main design for the study","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","","fee09dd7-6645-457a-8ded-2a0fefab2ddc"
